Share on Facebook Share on Twitter Email
Answers.com

CSL Limited

 
Hoover's Profile: CSL Limited
(Australian:CSL)
Contact Information
CSL Limited
45 Poplar Rd.
Parkville, Victoria 3052, Australia
Tel. +61-3-9389-1911
Fax +61-3-9389-1434

Type: Public
On the web: http://www.csl.com.au

Water into wine, base metal into gold ... sure, these are nice, but Australia's CSL Limited regularly turns human plasma into life-saving products used the world over. The company has three divisions: its largest business, CSL Behring, develops plasma protein therapies for blood disorders, immune system deficiencies, and other health ailments. Its CSL Biotherapies unit produces influenza vaccines (flu shots) sold in Australia, the US, and other countries, and CSL Bioplasma provides plasma processing services and diagnostic products. CSL has manufacturing facilities in Australia, Europe, and the US.

Key numbers for fiscal year ending June, 2009:
Sales: $4,003.2M
One year growth: 10.6%
Net income: $921.9M
Income growth: 36.8%

Officers:
Chairman: Elizabeth A. Alexander
CEO and Managing Director: Brian A. McNamee
Finance Director and Board Member: Antoni M. (Tony) Cipa

Competitors:
Baxter International
Grifols
Novartis

Search unanswered questions...
Enter a question here...
Search: All sources Community Q&A Reference topics
Wikipedia: CSL Limited
Top
CSL Limited
Type Public (ASX: CSL)
Founded 1994 (privatised), 1916 (government department)
Headquarters Melbourne,  Australia Australia
Key people Brian A McNamee (CEO)
Industry medicine
Products blood plasma, vaccines, antivenom, other laboratory and medical products
Revenue $3,310 million AUD (Y.E. 30 June 2007)
Website www.csl.com.au

CSL Limited is an Australian-based manufacturer of medical products. Its products include various blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing.

Contents

History

Founded in 1916 the Commonwealth Serum Laboratories, an Australian government body focused on vaccine manufacture. Under the first director, Australian-born William Penfold, CSL commenced operation in the vacant Walter and Eliza Hall Institute building at the Melbourne Hospital in 1918, before moving to its purpose-built Parkville premises in the following year. After ongoing disputes with the Commonwealth Department of Health and its director, (John) Howard Cumpston, Penfold resigned in 1927 and was replaced by Frederic Morgan. Soon after Morgan's appointment, CSL was drawn into a serious public health disaster when a batch of its diphtheria toxin-antitoxin was implicated in the deaths of 12 children in what became known as the 'Bundaberg tragedy' of 1928. Although CSL's manufacturing processes were absolved, its labelling procedures were seen to be in error, leading to an enduring focus on the highest standards across the facility's production. In 1928 CSL also became involved in antivenene (antivenom) manufacture in conjunction with the snake venom research undertaken by Charles Kellaway at the Hall Institute. This led to the successful clinical testing of antivenene against tiger snake Notechis scutatus bite in 1930, and its commercial release in 1931. In 1934 the research on snake venoms was transferred from the Hall Institute to CSL under the direction of former snake showman, Tom 'Pambo' Eades. This represented the initiation of research at the Laboratories - an outcome its directors had been seeking for over a decade. The relationship with the Hall Institute continued until World War II, particularly via joint projects on viral diseases including polio and influenza coordinated by Frank Macfarlane Burnet and Esmond 'Bill' Keogh. Keogh played an important role in the establishment of penicillin production at CSL in 1944 - a critical wartime achievement.

The operation commenced plasma fractionation in 1952. Thereafter the range of antivenoms increased, including those against other snake species such as death adder (Acanthophis antarcticus) and the taipan (Oxyuranus scutellatus), plus spiders including the redback (Latrodectus hasselti) and - after much difficulty - the Sydney funnnel-web (Atrax robustus). Much of this work, including the introduction in 1962 of a polyvalent antivenom against all of the major terrestrial Australian snakes, occurred under the direction of Saul Wiener, while from 1966 until the mid-1990s, venom research was coordinated by the eccentric but dedicated Struan Sutherland.

This former Commonwealth facility was privatised as CSL Ltd in 1994. In 2000 CSL doubled its size through the purchase of a Swiss plasma company, the Bern-based ZLB Bioplasma AG. In 2004, during a period of plasma oversupply, the company expanded again with the purchase of the German medical company Aventis Behring. The company was the 2nd Australian public company to have reached a share price of over $100 per share.

Locations

The company's headquarters remain in Parkville, Victoria, an inner suburb of Melbourne. CSL Behring is headquartered in King of Prussia, Pennsylvania and has manufacturing operations in the Swiss city of Berne, in Marburg in Germany, and Kankakee, Illinois.

Ownership

CSL is a public company whose stock is traded on the Australian Securities Exchange under the stock code CSL. The company completed an Initial Public Offering in June 1994 at A$2.30 per share. Today CSL stock is part of the S&P/ASX 50 Index.

Vaccine for A/H1N1 2009 Pandemic

CSL's vaccine for Swine Flu was approved in September 2009 for use in Australia by people aged 10 and over.[1] The federal government ordered 21 million doses of vaccine for 2009 A/H1N1 of which 8 million were manufactured by CSL. The Australian government intends to use the CSL Vaccine in one of the largest national vaccine programs in the country's history.

Products

CSL Limited's products can be separated by company division.

Some of the key products produced by each division, have included:

CSL Vaccines

Vaccines

Antivenoms

CSL Biotherapies

CSL Behring

  • Beriate, which is freeze-dried human factor VIII concentrate
  • Berinin, freeze-dried human factor IX concentrate
  • Helixate FS, freeze-dried recombinant coagulation factor VIII. CSL is working on a new Helixate product called "Helixate NexGen".
  • Humate-P, freeze-dried human coagulation factor VIII/von Willebrand factor complex
  • Monoclate, a freeze-dried human coagulation factor VIII that has been purified using monoclonal antibodies
  • Mononine, a freeze-dried human coagulation factor IX that has been purified using monoclonal antibodies
  • Stimate, a synthetic desmopressin acetate nasal spray

CSL Bioplasma

See also

References

  • AH Brogan, Committed to Saving Lives: a History of the Commonwealth Serum Laboratories (Melbourne: Hyland House, 1990).
  • Dando McCredie, The Fight Against Disease and CSL's Seventy Year Contribution (Richmond: Dando McCredie, c.1986).
  • FG Morgan, 'The Commonwealth Serum Laboratories and their work', Collected Proceedings of the Society of Chemical Industry of Victoria, XXXV (1935), 1015–31.
  • WJ Penfold, 'The Commonwealth Serum Laboratories', Medical Journal of Australia, 1 (14 April 1923), 396–400.
  • Struan K Sutherland, A Venomous Life: the Autobiography of Professor Struan Sutherland (Melbourne: Hyland House, 1998).

Notes

  1. ^ "Panvax® H1N1 Approval For Registration For Use in Australia by Therapeutic Goods Administration". Melbourne, Australia: CSL Limited. 18 September 2009. Archived from the original on 18 September 2009. http://www.webcitation.org/5jt4RxSfr. Retrieved 26 September 2009. "CSL Biotherapies, a subsidiary of CSL Limited, Australia's leading biopharmaceutical company, can today confirm that its vaccine against the pandemic (H1N1) 200 influenza or 'swine flu' has been approved registration for use in people aged 10 years and over." 

 
 

 

Copyrights:

Hoover's Profile. ©2008 Hoover's, Inc. All rights reserved.  Read more
Wikipedia. This article is licensed under the Creative Commons Attribution/Share-Alike License. It uses material from the Wikipedia article "CSL Limited" Read more